Comparison of In Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat, and Mouse Liver Microsomes

Background and Objectives Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, ra...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of drug metabolism and pharmacokinetics Vol. 44; no. 2; pp. 261 - 274
Main Authors Bhattacharya, Chandrali, Kirby, Danielle, Van Stipdonk, Michael, Stratford, Robert E.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.04.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background and Objectives Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations  for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans. Methods Hepatic microsomal incubations were conducted separately for the R - and S -bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CL int ) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship. Results The total clearance of S -bupropion was higher than that of R -bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively.  In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance. Conclusion The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability.
AbstractList Background and Objectives Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations  for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans. Methods Hepatic microsomal incubations were conducted separately for the R - and S -bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CL int ) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship. Results The total clearance of S -bupropion was higher than that of R -bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively.  In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance. Conclusion The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability.
Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations  for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans. Hepatic microsomal incubations were conducted separately for the R- and S-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CL ) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship. The total clearance of S-bupropion was higher than that of R-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively.  In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance. The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability.
Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans.BACKGROUND AND OBJECTIVESBupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of three phase I metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) in human, marmoset, rat, and mouse liver microsomes. The objective was to establish suitability and limitations for subsequent use of nonclinical species to model bupropion central nervous system (CNS) disposition in humans.Hepatic microsomal incubations were conducted separately for the R- and S-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CLint) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship.METHODSHepatic microsomal incubations were conducted separately for the R- and S-bupropion enantiomers, and the formation of enantiomer-specific metabolites was determined using LC-MS/MS. Intrinsic formation clearance (CLint) of metabolites across the four species was determined from the formation rate versus substrate concentration relationship.The total clearance of S-bupropion was higher than that of R-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance.RESULTSThe total clearance of S-bupropion was higher than that of R-bupropion in monkey and human liver microsomes. The contribution of hydroxybupropion to the total racemic bupropion clearance was 38%, 62%, 17%, and 96% in human, monkey, rat, and mouse, respectively. In the same species order, threohydrobupropion contributed 53%, 23%, 17%, and 3%, and erythrohydrobupropion contributed 9%, 14%, 66%, and 1.3%, respectively, to racemic bupropion clearance.The results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability.CONCLUSIONThe results demonstrate that phase I metabolism in monkeys best approximates that observed in humans, and support the preferred use of this species to investigate possible pharmacokinetic factors that influence the CNS disposition of bupropion and contribute to its high intersubject variability.
Author Van Stipdonk, Michael
Bhattacharya, Chandrali
Stratford, Robert E.
Kirby, Danielle
Author_xml – sequence: 1
  givenname: Chandrali
  surname: Bhattacharya
  fullname: Bhattacharya, Chandrali
  organization: Graduate School of Pharmaceutical Sciences, Duquesne University, Department of Pharmacy Practice, Purdue University
– sequence: 2
  givenname: Danielle
  surname: Kirby
  fullname: Kirby, Danielle
  organization: Department of Chemistry and Biochemistry, Duquesne University
– sequence: 3
  givenname: Michael
  surname: Van Stipdonk
  fullname: Van Stipdonk, Michael
  organization: Department of Chemistry and Biochemistry, Duquesne University
– sequence: 4
  givenname: Robert E.
  surname: Stratford
  fullname: Stratford, Robert E.
  email: robstrat@iu.edu
  organization: Graduate School of Pharmaceutical Sciences, Duquesne University, Indiana University School of Medicine, Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30298475$$D View this record in MEDLINE/PubMed
BookMark eNp9kc9r2zAUgMXIWLMsf8AuQ8ce4k6yZEs-tmFbAwmFbu1VyPbzUGdLriQX-t9PJs2lhwgegsf3Pd6Pz2hhnQWEvlJyRQkR3wNljMqMzFHQMuMf0DKnRMwZskBLwoTMRFWWF2gdwhNJj8mqKMpP6IKRvJJcFEs0bt0wam-Cs9h1eGfxo4ne4d8RPLgAPTTRvAA-QNS1600YZuxmGr0bTXKMxbfToO0GH5z9B68bfK_jBmvbpsQUAO-T7fHBNN4FN0D4gj52ug-wfvtX6OHnjz_b22x_92u3vd5nDeM8ZqKrQPJatmWuQVMA3jFRlG0lWF7WlBdCcqgktCAbyanWEhpeE2i0JC2VOVuhy2Pd1OnzBCGqwYQG-l5bSI2pnFLBqkJWJKHf3tCpHqBVozeD9q_qtKUEiCMwDxE8dKoxUcc0f_Ta9IoSNZ9EHU-iyBzpJIonk74zT8XPOfnRCYm1f8GrJzd5m5Z1RvoP7fidXg
CitedBy_id crossref_primary_10_1016_j_jpba_2020_113872
crossref_primary_10_1124_dmd_122_000867
crossref_primary_10_1007_s11419_021_00595_6
crossref_primary_10_2174_0113892002302675240903075500
crossref_primary_10_3390_genes11070729
crossref_primary_10_1007_s13318_023_00817_9
crossref_primary_10_1080_03602532_2019_1620763
crossref_primary_10_1021_acs_jafc_4c00969
Cites_doi 10.1124/jpet.110.166850
10.1124/mol.104.001313
10.1002/mds.21425
10.1097/FBP.0b013e328345ca37
10.1124/dmd.108.023119
10.1001/archpsyc.1988.01800260055007
10.1093/ntr/nts088
10.1124/dmd.115.063107
10.1056/NEJMp1212969
10.1124/dmd.115.068932
10.1097/00008571-200404000-00002
10.1080/03602532.2016.1221960
10.1124/dmd.116.072363
10.4088/PCC.v07n0305
10.1124/dmd.115.068908
10.2133/dmpk.DMPK-13-RG-051
10.1016/j.bcp.2011.04.014
10.1097/00004714-199002000-00018
10.1124/dmd.113.052936
10.1016/j.biopsych.2004.12.007
10.1002/bdd.2046
10.1016/j.vascn.2014.12.005
10.1002/9781118286067
10.1124/dmd.111.043554
10.1186/1744-859X-7-19
10.1124/jpet.116.232876
10.1038/clpt.1985.228
10.1007/s11095-008-9535-1
10.4088/JCP.v59n0705
10.1081/DMR-120034149
10.4088/PCC.v04n0110a
10.1177/0091270008314254
10.1097/FPC.0b013e32835d9ab0
10.1055/s-2007-1014505
10.1038/sj.tpj.6500281
10.1016/j.brainres.2010.06.035
10.3109/00498258709043939
10.1208/s12248-017-0102-8
10.1016/S0028-3908(03)00136-9
10.4088/PCC.v06n0403
10.1016/j.tips.2011.08.005
10.1038/npp.2010.202
10.1097/00004583-200208000-00009
10.2165/00002018-200831110-00006
10.1038/npp.2008.110
10.1016/S0014-2999(03)02010-7
10.1124/dmd.114.060285
10.1002/syn.10242
10.1371/journal.pone.0002337
10.1037/a0022432
10.1007/978-3-211-45295-0_26
10.1038/clpt.2012.186
10.1016/B978-0-12-420118-7.00005-6
10.1097/01213011-200512000-00006
10.1016/S0006-3223(02)01664-5
10.1097/FBP.0000000000000224
10.1016/j.jchromb.2016.02.018
ContentType Journal Article
Copyright Springer Nature Switzerland AG 2018
Copyright_xml – notice: Springer Nature Switzerland AG 2018
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1007/s13318-018-0516-4
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2107-0180
EndPage 274
ExternalDocumentID 30298475
10_1007_s13318_018_0516_4
Genre Journal Article
GroupedDBID ---
-EM
06D
0R~
0VY
1N0
2JN
2KG
30V
4.4
406
408
40D
5GY
67N
96X
AABHQ
AACDK
AAIKX
AAJKR
AANZL
AARTL
AASML
AATNV
AAWCG
AAYIU
AAYQN
AAZMS
ABAKF
ABDZT
ABFTV
ABHLI
ABJNI
ABJOX
ABKCH
ABKMS
ABPLI
ABQBU
ABTKH
ABTMW
ABXPI
ACAOD
ACCOQ
ACDTI
ACGFS
ACKNC
ACMLO
ACPIV
ACZOJ
ADFZG
ADHHG
ADHIR
ADINQ
ADKPE
ADRFC
ADURQ
ADZKW
AEFQL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AFBBN
AFWTZ
AFZKB
AGAYW
AGDGC
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AJRNO
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
ASPBG
AVWKF
AWSVR
AXYYD
AZFZN
BGNMA
CSCUP
DNIVK
DPUIP
DU5
EBLON
EBS
EIOEI
EJD
ESBYG
F5P
FERAY
FFXSO
FIGPU
FLLZZ
FNLPD
FRRFC
FSGXE
GGRSB
GJIRD
GNWQR
GQ6
GQ7
H13
HF~
HMJXF
HRMNR
ITM
IWAJR
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NQJWS
NU0
P2P
R9I
RLLFE
ROL
RSV
S27
S3A
S3B
SBL
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPKJE
SRMVM
SSLCW
T13
TSG
U2A
U9L
UG4
UTJUX
UZXMN
VC2
VDBLX
VFIZW
W48
WK8
Z45
Z7U
Z87
~A9
~JE
.GJ
2.D
2VQ
53G
AAAUJ
AAEWM
AAIAL
AANXM
AARHV
AAYOK
AAYTO
AAYXX
AAYZH
ABBRH
ABDBE
ABFSG
ABWHX
ACBXY
ACSTC
ADYPR
AEBTG
AEKMD
AEYRQ
AEZWR
AFDZB
AFHIU
AFLOW
AFOHR
AGJBK
AHWEU
AILAN
AIXLP
AJBLW
ATHPR
AYFIA
BBWZM
CITATION
EN4
FEDTE
HVGLF
HZ~
O9-
S1Z
SBY
SCLPG
ABRTQ
NPM
7X8
ID FETCH-LOGICAL-c344t-7f9e84b8d62aea1ee4f3756d97326b145784e98ede8c841aa8ec4b0eca80d1823
IEDL.DBID U2A
ISSN 0378-7966
2107-0180
IngestDate Thu Jul 10 19:35:19 EDT 2025
Mon Jul 21 06:04:34 EDT 2025
Thu Apr 24 22:51:22 EDT 2025
Tue Jul 01 04:04:10 EDT 2025
Fri Feb 21 02:35:52 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c344t-7f9e84b8d62aea1ee4f3756d97326b145784e98ede8c841aa8ec4b0eca80d1823
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PMID 30298475
PQID 2117395890
PQPubID 23479
PageCount 14
ParticipantIDs proquest_miscellaneous_2117395890
pubmed_primary_30298475
crossref_citationtrail_10_1007_s13318_018_0516_4
crossref_primary_10_1007_s13318_018_0516_4
springer_journals_10_1007_s13318_018_0516_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-04-01
PublicationDateYYYYMMDD 2019-04-01
PublicationDate_xml – month: 04
  year: 2019
  text: 2019-04-01
  day: 01
PublicationDecade 2010
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: France
PublicationTitle European journal of drug metabolism and pharmacokinetics
PublicationTitleAbbrev Eur J Drug Metab Pharmacokinet
PublicationTitleAlternate Eur J Drug Metab Pharmacokinet
PublicationYear 2019
Publisher Springer International Publishing
Publisher_xml – name: Springer International Publishing
References Kielbasa, Stratford (CR53) 2012; 40
Connarn (CR15) 2017; 19
CR38
Benowitz (CR13) 2013; 23
CR32
Dalgaard (CR59) 2015; 74
Wang (CR60) 2011; 82
Schindler (CR61) 2011; 19
Sager, Price, Isoherranen (CR28) 2016; 44
Volkow (CR36) 2005; 57
Silverstone (CR29) 2008; 7
Cremers (CR48) 2016; 44
Woodcock, Khan, Yu (CR7) 2012; 367
Beyens (CR19) 2008; 31
Hansard (CR51) 2011; 22
CR2
Avdeef (CR64) 2012
Sharon, Tyndale (CR45) 2009; 34
Khokhar, Tyndale (CR43) 2011; 36
CR6
CR5
Davidson (CR17) 1990; 10
Hesse (CR10) 2004; 14
Damaj (CR26) 2010; 334
Ascher (CR37) 1995; 56
CR42
Grandas, López-Manzanares (CR16) 2007; 22
Suckow (CR24) 1986; 14
Damaj (CR25) 2004; 66
Kharasch, Mitchell, Coles (CR22) 2008; 48
Meyer (CR50) 2013; 41
Fava (CR1) 2005; 7
Deveaugh-Geiss (CR35) 2002; 41
Golden (CR8) 1988; 45
Skarydova (CR30) 2014; 29
Gufford (CR20) 2016; 44
Martin (CR39) 1990; 23
Khokhar, Miksys, Tyndale (CR47) 2010; 1348
CR12
Reimherr (CR3) 2005; 1
CR54
Miksys (CR63) 2003; 45
Connarn (CR9) 2016; 37
Ferguson, Tyndale (CR44) 2011; 32
Masters (CR21) 2016; 358
Dunner, Billow (CR55) 1998; 59
Berigan (CR4) 2002; 4
Swan (CR31) 2004; 5
Kielbasa, Kalvass, Stratford (CR52) 2009; 37
Coles, Kharasch (CR23) 2008; 25
Stahl (CR56) 2004; 6
Zhu (CR14) 2014; 42
CR27
Connarn (CR57) 2015; 43
Grabus, Carroll, Damaj (CR34) 2012; 14
Laizure (CR11) 1985; 38
Agarwal (CR40) 2008; 3
Welch, Lai, Schroeder (CR49) 1987; 17
Bondarev (CR33) 2003; 474
CR62
Johnston, Ascher (CR18) 1991; 52
Bruijnzeel, Markou (CR58) 2003; 50
Toselli, Dodd, Gillam (CR46) 2016; 48
Miksys, Tyndale (CR41) 2004; 36
DL Dunner (516_CR55) 1998; 59
LM Hesse (516_CR10) 2004; 14
SC Laizure (516_CR11) 1985; 38
V Agarwal (516_CR40) 2008; 3
P Martin (516_CR39) 1990; 23
J Woodcock (516_CR7) 2012; 367
S Miksys (516_CR41) 2004; 36
JN Connarn (516_CR57) 2015; 43
516_CR2
JN Connarn (516_CR15) 2017; 19
MJ Hansard (516_CR51) 2011; 22
SM Stahl (516_CR56) 2004; 6
AZX Zhu (516_CR14) 2014; 42
516_CR42
RM Welch (516_CR49) 1987; 17
BT Gufford (516_CR20) 2016; 44
A Avdeef (516_CR64) 2012
MI Damaj (516_CR25) 2004; 66
JY Khokhar (516_CR47) 2010; 1348
GE Swan (516_CR31) 2004; 5
JE Sager (516_CR28) 2016; 44
ND Volkow (516_CR36) 2005; 57
CS Ferguson (516_CR44) 2011; 32
RF Suckow (516_CR24) 1986; 14
516_CR38
FW Reimherr (516_CR3) 2005; 1
L Skarydova (516_CR30) 2014; 29
TIFH Cremers (516_CR48) 2016; 44
NL Benowitz (516_CR13) 2013; 23
516_CR32
A Meyer (516_CR50) 2013; 41
J Deveaugh-Geiss (516_CR35) 2002; 41
AW Bruijnzeel (516_CR58) 2003; 50
X Wang (516_CR60) 2011; 82
ED Kharasch (516_CR22) 2008; 48
S Miksys (516_CR63) 2003; 45
JY Khokhar (516_CR43) 2011; 36
M-N Beyens (516_CR19) 2008; 31
JALC Johnston (516_CR18) 1991; 52
AR Masters (516_CR21) 2016; 358
CW Schindler (516_CR61) 2011; 19
RN Golden (516_CR8) 1988; 45
PH Silverstone (516_CR29) 2008; 7
R Coles (516_CR23) 2008; 25
W Kielbasa (516_CR53) 2012; 40
516_CR27
ML Bondarev (516_CR33) 2003; 474
M Fava (516_CR1) 2005; 7
JA Ascher (516_CR37) 1995; 56
JN Connarn (516_CR9) 2016; 37
516_CR62
MI Damaj (516_CR26) 2010; 334
J Davidson (516_CR17) 1990; 10
L Dalgaard (516_CR59) 2015; 74
516_CR5
516_CR6
W Kielbasa (516_CR52) 2009; 37
M Sharon (516_CR45) 2009; 34
TR Berigan (516_CR4) 2002; 4
F Toselli (516_CR46) 2016; 48
516_CR12
SD Grabus (516_CR34) 2012; 14
F Grandas (516_CR16) 2007; 22
516_CR54
References_xml – volume: 334
  start-page: 1087
  issue: 3
  year: 2010
  end-page: 1095
  ident: CR26
  article-title: Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice
  publication-title: J Pharmacol Experim Therapeut
  doi: 10.1124/jpet.110.166850
– volume: 66
  start-page: 675
  issue: 3
  year: 2004
  ident: CR25
  article-title: Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.104.001313
– volume: 56
  start-page: 395
  issue: 9
  year: 1995
  end-page: 401
  ident: CR37
  article-title: Bupropion: a review of its mechanism of antidepressant activity
  publication-title: J Clin Psychiatry
– volume: 22
  start-page: 1830
  issue: 12
  year: 2007
  end-page: 1831
  ident: CR16
  article-title: Bupropion-induced parkinsonism
  publication-title: Mov Disord
  doi: 10.1002/mds.21425
– volume: 22
  start-page: 269
  issue: 3
  year: 2011
  end-page: 274
  ident: CR51
  article-title: A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets
  publication-title: Behav Pharmacol
  doi: 10.1097/FBP.0b013e328345ca37
– volume: 37
  start-page: 137
  issue: 1
  year: 2009
  end-page: 142
  ident: CR52
  article-title: Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.108.023119
– volume: 45
  start-page: 145
  issue: 2
  year: 1988
  end-page: 149
  ident: CR8
  article-title: Bupropion in depression. II. The role of metabolites in clinical outcome
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1988.01800260055007
– ident: CR12
– volume: 14
  start-page: 1356
  issue: 11
  year: 2012
  end-page: 1361
  ident: CR34
  article-title: Bupropion and its main metabolite reverse nicotine chronic tolerance in the mouse
  publication-title: Nicotine Tob Res
  doi: 10.1093/ntr/nts088
– volume: 43
  start-page: 1019
  issue: 7
  year: 2015
  end-page: 1027
  ident: CR57
  article-title: Metabolism of bupropion by carbonyl reductases in liver and intestine
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.063107
– volume: 367
  start-page: 2463
  issue: 26
  year: 2012
  end-page: 2465
  ident: CR7
  article-title: Withdrawal of generic budeprion for nonbioequivalence
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp1212969
– volume: 44
  start-page: 624
  issue: 5
  year: 2016
  end-page: 633
  ident: CR48
  article-title: Development of a rat plasma and brain extracellular fluid pharmacokinetic model for bupropion and hydroxybupropion based on microdialysis sampling, and application to predict human brain concentrations
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.068932
– ident: CR54
– volume: 14
  start-page: 225
  issue: 4
  year: 2004
  end-page: 238
  ident: CR10
  article-title: Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/00008571-200404000-00002
– volume: 48
  start-page: 379
  issue: 3
  year: 2016
  end-page: 404
  ident: CR46
  article-title: Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs
  publication-title: Drug Metab Rev
  doi: 10.1080/03602532.2016.1221960
– volume: 52
  start-page: 450
  year: 1991
  end-page: 456
  ident: CR18
  article-title: A 102-center prospective study of seizure in association with bupropion
  publication-title: J Clin Psychiatry
– volume: 44
  start-page: 1709
  issue: 10
  year: 2016
  end-page: 1719
  ident: CR28
  article-title: Stereoselective metabolism of bupropion to OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4′-OH-bupropion in vitro
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.116.072363
– volume: 7
  start-page: 106
  issue: 3
  year: 2005
  end-page: 113
  ident: CR1
  article-title: 15 years of clinical experience with bupropion HCL: from bupropion to bupropion SR to bupropion XL
  publication-title: Prim Care Compan J Clin Psychiatry
  doi: 10.4088/PCC.v07n0305
– volume: 44
  start-page: 544
  issue: 4
  year: 2016
  end-page: 553
  ident: CR20
  article-title: Stereoselective glucuronidation of bupropion metabolites in vitro and in vivo
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.068908
– volume: 29
  start-page: 177
  issue: 2
  year: 2014
  end-page: 184
  ident: CR30
  article-title: Deeper insight into the reducing biotransformation of bupropion in the human liver
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-13-RG-051
– ident: CR42
– volume: 82
  start-page: 295
  issue: 3
  year: 2011
  end-page: 303
  ident: CR60
  article-title: Metabolism of bupropion by baboon hepatic and placental microsomes
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2011.04.014
– volume: 10
  start-page: 60
  issue: 1
  year: 1990
  end-page: 62
  ident: CR17
  article-title: Seizures and bupropion: a review
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-199002000-00018
– volume: 1
  start-page: 245
  issue: 3
  year: 2005
  end-page: 251
  ident: CR3
  article-title: Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial
  publication-title: Neuropsychiatr Dis Treatm
– volume: 41
  start-page: 1671
  issue: 9
  year: 2013
  end-page: 1678
  ident: CR50
  article-title: Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.113.052936
– volume: 57
  start-page: 640
  issue: 6
  year: 2005
  end-page: 646
  ident: CR36
  article-title: The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects
  publication-title: Biol Psychiat
  doi: 10.1016/j.biopsych.2004.12.007
– volume: 37
  start-page: 550
  issue: 9
  year: 2016
  end-page: 560
  ident: CR9
  article-title: Identification of non-reported bupropion metabolites in human plasma
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/bdd.2046
– volume: 74
  start-page: 80
  year: 2015
  end-page: 92
  ident: CR59
  article-title: Comparison of minipig, dog, monkey and human drug metabolism and disposition
  publication-title: J Pharmacol Toxicol Methods
  doi: 10.1016/j.vascn.2014.12.005
– start-page: 595
  year: 2012
  ident: CR64
  publication-title: Permeability: blood-brain barrier in absorption and drug development solubility, permeability, and charge state
  doi: 10.1002/9781118286067
– volume: 40
  start-page: 877
  issue: 5
  year: 2012
  end-page: 883
  ident: CR53
  article-title: Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.043554
– volume: 7
  start-page: 19
  year: 2008
  ident: CR29
  article-title: Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice
  publication-title: Ann Gen Psychiatry
  doi: 10.1186/1744-859X-7-19
– volume: 358
  start-page: 230
  issue: 2
  year: 2016
  end-page: 238
  ident: CR21
  article-title: Chiral plasma pharmacokinetics and urinary excretion of bupropion and metabolites in healthy volunteers
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.116.232876
– ident: CR32
– volume: 38
  start-page: 586
  issue: 5
  year: 1985
  end-page: 589
  ident: CR11
  article-title: Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.1985.228
– volume: 25
  start-page: 1405
  issue: 6
  year: 2008
  end-page: 1411
  ident: CR23
  article-title: Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes
  publication-title: Pharm Res
  doi: 10.1007/s11095-008-9535-1
– ident: CR5
– volume: 59
  start-page: 366
  year: 1998
  end-page: 373
  ident: CR55
  article-title: A prospective safety surveillance study for bupropion sustained-release in the treatment of depression
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v59n0705
– volume: 36
  start-page: 313
  issue: 2
  year: 2004
  end-page: 333
  ident: CR41
  article-title: The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics
  publication-title: Drug Metab Rev
  doi: 10.1081/DMR-120034149
– ident: CR2
– volume: 4
  start-page: 30
  issue: 1
  year: 2002
  end-page: 32
  ident: CR4
  article-title: The many uses of bupropion and bupropion sustained release (SR) in adults
  publication-title: Prim Care Compan J Clin Psychiatry
  doi: 10.4088/PCC.v04n0110a
– volume: 48
  start-page: 464
  issue: 4
  year: 2008
  end-page: 474
  ident: CR22
  article-title: Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270008314254
– volume: 23
  start-page: 135
  issue: 3
  year: 2013
  end-page: 141
  ident: CR13
  article-title: Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32835d9ab0
– volume: 23
  start-page: 187
  issue: 04
  year: 1990
  end-page: 194
  ident: CR39
  article-title: Antidepressant profile of bupropion and three metabolites in mice
  publication-title: Pharmacopsychiatry
  doi: 10.1055/s-2007-1014505
– ident: CR6
– volume: 5
  start-page: 21
  year: 2004
  ident: CR31
  article-title: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR
  publication-title: Pharmacogenomics J
  doi: 10.1038/sj.tpj.6500281
– volume: 1348
  start-page: 1
  year: 2010
  end-page: 9
  ident: CR47
  article-title: Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2010.06.035
– ident: CR27
– volume: 17
  start-page: 287
  issue: 3
  year: 1987
  end-page: 298
  ident: CR49
  article-title: Pharmacological significance of the species differences in bupropion metabolism
  publication-title: Xenobiotica
  doi: 10.3109/00498258709043939
– volume: 19
  start-page: 1513
  issue: 5
  year: 2017
  end-page: 1522
  ident: CR15
  article-title: Pharmacokinetics and pharmacogenomics of bupropion in three different formulations with different release kinetics in healthy human volunteers
  publication-title: AAPS J
  doi: 10.1208/s12248-017-0102-8
– volume: 45
  start-page: 122
  issue: 1
  year: 2003
  end-page: 132
  ident: CR63
  article-title: Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(03)00136-9
– volume: 6
  start-page: 159
  issue: 4
  year: 2004
  end-page: 166
  ident: CR56
  article-title: A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor
  publication-title: Prim Care Compan J Clin Psychiatry
  doi: 10.4088/PCC.v06n0403
– ident: CR38
– volume: 32
  start-page: 708
  issue: 12
  year: 2011
  end-page: 714
  ident: CR44
  article-title: Cytochromes P450 in the brain: emerging evidence for biological significance
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2011.08.005
– volume: 36
  start-page: 692
  issue: 3
  year: 2011
  end-page: 700
  ident: CR43
  article-title: Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2010.202
– volume: 41
  start-page: 914
  issue: 8
  year: 2002
  end-page: 920
  ident: CR35
  article-title: GW320659 for the treatment of attention-deficit/hyperactivity disorder in children
  publication-title: J Am Acad Child Adolesc Psychiatry
  doi: 10.1097/00004583-200208000-00009
– volume: 31
  start-page: 1017
  issue: 11
  year: 2008
  end-page: 1026
  ident: CR19
  article-title: Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004
  publication-title: Drug Saf
  doi: 10.2165/00002018-200831110-00006
– volume: 34
  start-page: 634
  issue: 3
  year: 2009
  end-page: 640
  ident: CR45
  article-title: Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2008.110
– volume: 474
  start-page: 85
  issue: 1
  year: 2003
  end-page: 93
  ident: CR33
  article-title: Behavioral and biochemical investigations of bupropion metabolites
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(03)02010-7
– ident: CR62
– volume: 42
  start-page: 1971
  issue: 11
  year: 2014
  end-page: 1977
  ident: CR14
  article-title: Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.114.060285
– volume: 14
  start-page: 692
  issue: 6
  year: 1986
  end-page: 697
  ident: CR24
  article-title: Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs
  publication-title: Drug Metab Dispos
– volume: 50
  start-page: 20
  issue: 1
  year: 2003
  end-page: 28
  ident: CR58
  article-title: Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats
  publication-title: Synapse
  doi: 10.1002/syn.10242
– volume: 3
  start-page: e2337
  issue: 6
  year: 2008
  ident: CR40
  article-title: Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0002337
– volume: 19
  start-page: 1
  issue: 1
  year: 2011
  end-page: 10
  ident: CR61
  article-title: Comparison of the effects of methamphetamine, bupropion and methylphenidate on the self-administration of methamphetamine by rhesus monkeys
  publication-title: Exp Clin Psychopharmacol
  doi: 10.1037/a0022432
– ident: 516_CR42
  doi: 10.1007/978-3-211-45295-0_26
– ident: 516_CR12
  doi: 10.1038/clpt.2012.186
– volume: 23
  start-page: 135
  issue: 3
  year: 2013
  ident: 516_CR13
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e32835d9ab0
– volume: 6
  start-page: 159
  issue: 4
  year: 2004
  ident: 516_CR56
  publication-title: Prim Care Compan J Clin Psychiatry
  doi: 10.4088/PCC.v06n0403
– volume: 34
  start-page: 634
  issue: 3
  year: 2009
  ident: 516_CR45
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2008.110
– volume: 37
  start-page: 550
  issue: 9
  year: 2016
  ident: 516_CR9
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/bdd.2046
– volume: 29
  start-page: 177
  issue: 2
  year: 2014
  ident: 516_CR30
  publication-title: Drug Metab Pharmacokinet
  doi: 10.2133/dmpk.DMPK-13-RG-051
– volume: 41
  start-page: 1671
  issue: 9
  year: 2013
  ident: 516_CR50
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.113.052936
– volume: 38
  start-page: 586
  issue: 5
  year: 1985
  ident: 516_CR11
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.1985.228
– volume: 44
  start-page: 544
  issue: 4
  year: 2016
  ident: 516_CR20
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.068908
– ident: 516_CR27
  doi: 10.1016/B978-0-12-420118-7.00005-6
– ident: 516_CR2
– ident: 516_CR32
  doi: 10.1097/01213011-200512000-00006
– volume: 37
  start-page: 137
  issue: 1
  year: 2009
  ident: 516_CR52
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.108.023119
– volume: 1348
  start-page: 1
  year: 2010
  ident: 516_CR47
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2010.06.035
– volume: 19
  start-page: 1513
  issue: 5
  year: 2017
  ident: 516_CR15
  publication-title: AAPS J
  doi: 10.1208/s12248-017-0102-8
– volume: 7
  start-page: 19
  year: 2008
  ident: 516_CR29
  publication-title: Ann Gen Psychiatry
  doi: 10.1186/1744-859X-7-19
– volume: 82
  start-page: 295
  issue: 3
  year: 2011
  ident: 516_CR60
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2011.04.014
– volume: 56
  start-page: 395
  issue: 9
  year: 1995
  ident: 516_CR37
  publication-title: J Clin Psychiatry
– volume: 66
  start-page: 675
  issue: 3
  year: 2004
  ident: 516_CR25
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.104.001313
– volume: 14
  start-page: 1356
  issue: 11
  year: 2012
  ident: 516_CR34
  publication-title: Nicotine Tob Res
  doi: 10.1093/ntr/nts088
– volume: 7
  start-page: 106
  issue: 3
  year: 2005
  ident: 516_CR1
  publication-title: Prim Care Compan J Clin Psychiatry
  doi: 10.4088/PCC.v07n0305
– volume: 334
  start-page: 1087
  issue: 3
  year: 2010
  ident: 516_CR26
  publication-title: J Pharmacol Experim Therapeut
  doi: 10.1124/jpet.110.166850
– volume: 19
  start-page: 1
  issue: 1
  year: 2011
  ident: 516_CR61
  publication-title: Exp Clin Psychopharmacol
  doi: 10.1037/a0022432
– volume: 5
  start-page: 21
  year: 2004
  ident: 516_CR31
  publication-title: Pharmacogenomics J
  doi: 10.1038/sj.tpj.6500281
– ident: 516_CR38
– volume: 17
  start-page: 287
  issue: 3
  year: 1987
  ident: 516_CR49
  publication-title: Xenobiotica
  doi: 10.3109/00498258709043939
– volume: 74
  start-page: 80
  year: 2015
  ident: 516_CR59
  publication-title: J Pharmacol Toxicol Methods
  doi: 10.1016/j.vascn.2014.12.005
– volume: 45
  start-page: 122
  issue: 1
  year: 2003
  ident: 516_CR63
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(03)00136-9
– volume: 40
  start-page: 877
  issue: 5
  year: 2012
  ident: 516_CR53
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.111.043554
– ident: 516_CR5
– volume: 44
  start-page: 1709
  issue: 10
  year: 2016
  ident: 516_CR28
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.116.072363
– volume: 22
  start-page: 269
  issue: 3
  year: 2011
  ident: 516_CR51
  publication-title: Behav Pharmacol
  doi: 10.1097/FBP.0b013e328345ca37
– volume: 32
  start-page: 708
  issue: 12
  year: 2011
  ident: 516_CR44
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2011.08.005
– volume: 4
  start-page: 30
  issue: 1
  year: 2002
  ident: 516_CR4
  publication-title: Prim Care Compan J Clin Psychiatry
  doi: 10.4088/PCC.v04n0110a
– volume: 1
  start-page: 245
  issue: 3
  year: 2005
  ident: 516_CR3
  publication-title: Neuropsychiatr Dis Treatm
– volume: 44
  start-page: 624
  issue: 5
  year: 2016
  ident: 516_CR48
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.068932
– volume: 36
  start-page: 692
  issue: 3
  year: 2011
  ident: 516_CR43
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2010.202
– volume: 474
  start-page: 85
  issue: 1
  year: 2003
  ident: 516_CR33
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(03)02010-7
– ident: 516_CR6
  doi: 10.1016/S0006-3223(02)01664-5
– volume: 358
  start-page: 230
  issue: 2
  year: 2016
  ident: 516_CR21
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.116.232876
– volume: 57
  start-page: 640
  issue: 6
  year: 2005
  ident: 516_CR36
  publication-title: Biol Psychiat
  doi: 10.1016/j.biopsych.2004.12.007
– volume: 48
  start-page: 464
  issue: 4
  year: 2008
  ident: 516_CR22
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270008314254
– volume: 3
  start-page: e2337
  issue: 6
  year: 2008
  ident: 516_CR40
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0002337
– volume: 52
  start-page: 450
  year: 1991
  ident: 516_CR18
  publication-title: J Clin Psychiatry
– start-page: 595
  volume-title: Permeability: blood-brain barrier in absorption and drug development solubility, permeability, and charge state
  year: 2012
  ident: 516_CR64
  doi: 10.1002/9781118286067
– volume: 42
  start-page: 1971
  issue: 11
  year: 2014
  ident: 516_CR14
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.114.060285
– volume: 36
  start-page: 313
  issue: 2
  year: 2004
  ident: 516_CR41
  publication-title: Drug Metab Rev
  doi: 10.1081/DMR-120034149
– volume: 22
  start-page: 1830
  issue: 12
  year: 2007
  ident: 516_CR16
  publication-title: Mov Disord
  doi: 10.1002/mds.21425
– volume: 25
  start-page: 1405
  issue: 6
  year: 2008
  ident: 516_CR23
  publication-title: Pharm Res
  doi: 10.1007/s11095-008-9535-1
– volume: 14
  start-page: 692
  issue: 6
  year: 1986
  ident: 516_CR24
  publication-title: Drug Metab Dispos
– ident: 516_CR62
  doi: 10.1097/FBP.0000000000000224
– volume: 10
  start-page: 60
  issue: 1
  year: 1990
  ident: 516_CR17
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-199002000-00018
– volume: 367
  start-page: 2463
  issue: 26
  year: 2012
  ident: 516_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp1212969
– volume: 50
  start-page: 20
  issue: 1
  year: 2003
  ident: 516_CR58
  publication-title: Synapse
  doi: 10.1002/syn.10242
– ident: 516_CR54
  doi: 10.1016/j.jchromb.2016.02.018
– volume: 31
  start-page: 1017
  issue: 11
  year: 2008
  ident: 516_CR19
  publication-title: Drug Saf
  doi: 10.2165/00002018-200831110-00006
– volume: 23
  start-page: 187
  issue: 04
  year: 1990
  ident: 516_CR39
  publication-title: Pharmacopsychiatry
  doi: 10.1055/s-2007-1014505
– volume: 41
  start-page: 914
  issue: 8
  year: 2002
  ident: 516_CR35
  publication-title: J Am Acad Child Adolesc Psychiatry
  doi: 10.1097/00004583-200208000-00009
– volume: 45
  start-page: 145
  issue: 2
  year: 1988
  ident: 516_CR8
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1988.01800260055007
– volume: 43
  start-page: 1019
  issue: 7
  year: 2015
  ident: 516_CR57
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.115.063107
– volume: 48
  start-page: 379
  issue: 3
  year: 2016
  ident: 516_CR46
  publication-title: Drug Metab Rev
  doi: 10.1080/03602532.2016.1221960
– volume: 14
  start-page: 225
  issue: 4
  year: 2004
  ident: 516_CR10
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/00008571-200404000-00002
– volume: 59
  start-page: 366
  year: 1998
  ident: 516_CR55
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v59n0705
SSID ssj0000389556
Score 2.1978655
Snippet Background and Objectives Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared...
Bupropion is an atypical antidepressant and smoking cessation aid associated with wide intersubject variability. This study compared the formation kinetics of...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 261
SubjectTerms Biomedical and Life Sciences
Biomedicine
Human Physiology
Medical Biochemistry
Original Research Article
Pharmaceutical Sciences/Technology
Pharmacology/Toxicology
Pharmacy
Title Comparison of In Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat, and Mouse Liver Microsomes
URI https://link.springer.com/article/10.1007/s13318-018-0516-4
https://www.ncbi.nlm.nih.gov/pubmed/30298475
https://www.proquest.com/docview/2117395890
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9swED-N8rIXNBjbygDdpIkHSCS3thPnsSAY-yhCQCf2FDnJVaoESUXSh_73nPPRamKbtAe_RI4T-Xz273x3vwP4LFNtMyUzn7QMfGXJ-ImIUp_EMBJJYlVgXe7w-Cq4nKhv9_q-zeMuu2j3ziVZ79TrZDfJ649NX256wONuwKZm093FcU2Go9XFimOM07rxUbKFFDKe77yZfxrl9_PoBch84SCtz52LN7DVAkYcNRLehleU78DRdcM4vfTwbp1AVXp4hNdrLurlW5ifreoMYjHFrzn-nFVPBd7ydFJR1kVweL_DMVW8Gh5m5aPrdrrgP5yzxHCWY33N7yErP-u7hze28tDmGT9YlIQ_XFwHjl1YX1k8UrkLk4vzu7NLvy2y4KdSqcoPpxEZlZgsGFqyAyI1laEOMsfiEyQDxRqtKDKUkUmNGlhrKFWJoNQakbFxIt9BLy9y-gAoHbU87_3apBGjrMRSJkKS1oopw64o7IPopjpOWwZyVwjjIV5zJzvpxMI1lk6s-nC8emXe0G_8q_OnTn4xK4nzfNiceDJitnKdQ9JEog_vG8GuhpOOhF6Fug8nnaTjVo_Lv39r7796f4TXDLSiJuJnH3rV04IOGMxUySFsjr78-n5-WC_iZ6cD7CI
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VcoAL4k14lEGCHsCWNt61vT5w6IMqoUlVQYJ6c9f2RIrU2lHtCOX38EeZ9SNRVUDi0MNerPV6td_s7Ixn5luA9zL1TaZk5pIvA1cZ0m4iotQl4UUiSYwKjK0dHp8Eg6n6euafbcGvrhamznbvQpK1pt4Uu0mWP3Z9ufl9HrfNpDym1U_208rPw0MG9YPnHX2ZHAzc9ioBN5VKVW44i0irRGeBZ8j0idRMhn6QWa6aIOkrlltFkaaMdKpV3xhNqUoEpUaLjE1wyePegbtse2i7dabe3vpHjmWo8_0mJsoeWcj-Qxc9_dOsr59_N4zaGwHZ-pw7eggPWgMV9xqJegRblD-G3dOG4Xrl4GRTsFU6uIunG-7r1RNYHKzvNcRihsMcf8yrqwK_M3xUlPWlO6xfcUwVS9_FvLy03faXPMMFSwjOc6zDCg6ysmH94uA3Uzlo8owfLEvCkc0jwbFNIyyLSyqfwvRWkHgG23mR0wtAaans-azxdRqxVZcYykRI0hgxYzMvCnsguqWO05bx3F68cRFvuJotOrGwjdGJVQ8-rl9ZNHQf_-r8rsMv5k1pIy0mJ16MmL1qGwDVkejB8wbY9XDSkt6r0O_Bpw7puNUb5d-_9fK_er-Fe4PJeBSPhifHr-A-G3lRk230GrarqyW9YUOqSnZqQUY4v-2d8xs91Chc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIiEuiDfL00jQAySqN7YT58ChtKy6tFutoIt6C048kVZqk1WTFdpfxV9knMeuUAGJQw--RI4d-RvbM5mZbwDeiEwZK4X1UYnQlwa1n_I485EHMU9TI0PjcocnJ-HhTH4-U2db8LPPhWmi3XuXZJvT4Fiainp3YfPdTeKbIFkkM5iaGtIcXVTlEa5-kM1WfRgfEMBvg2D06XT_0O_KCviZkLL2ozxGLVNtw8CgGSLKXEQqtI63JkyHkmRYYqzRos60HBqjMZMpx8xobkkdFzTuDbgpXfIxbaBZsLf-qePY6pRq_aNknUVkS_Se1D999e934RUF94pztrnzRnfhTqessr1Wuu7BFhb3YWfasl2vPHa6Sd6qPLbDphse7NUDWOyvaxyyMmfjgn2b15cl-0pQYlk1BXjorGUTrEkSz-fVhev2cUlfuCBpYfOCNS4Gj9HBQ2eNx76Y2mOmsPRgWSE7djElbOJCCqvyAquHMLsWJB7BdlEW-ASYcLT2dO8oncWk4aUGLY9QGMNzUvniaAC8X-ok69jPXRGO82TD2-zQSbhrhE4iB_Bu_cqipf74V-fXPX4JbVDndTEF0mIkZGE7Z6iO-QAet8CuhxOOAF9GagDve6ST7gyp_j7X0__q_QpuTQ9GyfH45OgZ3CZ9L24Dj57Ddn25xBekU9Xpy0aOGXy_7o3zC2qbLI8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+In+Vitro+Stereoselective+Metabolism+of+Bupropion+in+Human%2C+Monkey%2C+Rat%2C+and+Mouse+Liver+Microsomes&rft.jtitle=European+journal+of+drug+metabolism+and+pharmacokinetics&rft.au=Bhattacharya%2C+Chandrali&rft.au=Kirby%2C+Danielle&rft.au=Van+Stipdonk%2C+Michael&rft.au=Stratford%2C+Robert+E.&rft.date=2019-04-01&rft.pub=Springer+International+Publishing&rft.issn=0378-7966&rft.eissn=2107-0180&rft.volume=44&rft.issue=2&rft.spage=261&rft.epage=274&rft_id=info:doi/10.1007%2Fs13318-018-0516-4&rft.externalDocID=10_1007_s13318_018_0516_4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-7966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-7966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-7966&client=summon